Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG
- PMID: 12960187
Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG
Abstract
Recently, the thymidine analog 3'-deoxy-3'-(18)F-fluorothymidine (FLT) was suggested for imaging tumoral proliferation. In this prospective study, we examined whether (18)F-FLT better determines proliferative activity in newly diagnosed lung nodules than does (18)F-FDG.
Methods: Twenty-six patients with pulmonary nodules on chest CT were examined with PET and the tracers (18)F-FDG and (18)F-FLT. Tumoral uptake was determined by calculation of standardized uptake value (SUV). Within 2 wk, patients underwent resective surgery or had core biopsy. Proliferative activity was estimated by counting nuclei stained with the Ki-67-specific monoclonal antibody MIB-1 per total number of nuclei in representative tissue specimens. The correlation between the percentage of proliferating cells and the SUVs for (18)F-FLT and (18)F-FDG was determined using linear regression analysis.
Results: Eighteen patients had malignant tumors (13 with non-small cell lung cancer [NSCLC], 1 with small cell lung cancer, and 4 with pulmonary metastases from extrapulmonary tumors); 8 had benign lesions. In all visible lesions, mean (18)F-FDG uptake was 4.1 (median, 4.4; SD, 3.0; range, 1.0-10.6), and mean (18)F-FLT uptake was 1.8 (median, 1.2; SD, 2.0; range, 0.8-6.4). Statistical analysis revealed a significantly higher uptake of (18)F-FDG than of (18)F-FLT (Mann-Whitney U test, P < 0.05). (18)F-FLT SUV correlated better with proliferation index (P < 0.0001; r = 0.92) than did (18)F-FDG SUV (P < 0.001; r = 0.59). With the exception of 1 carcinoma in situ, all malignant tumors showed increased (18)F-FDG PET uptake. (18)F-FLT PET was false-negative in the carcinoma in situ, in another NSCLC with a low proliferation index, and in a patient with lung metastases from colorectal cancer. Increased (18)F-FLT uptake was related exclusively to malignant tumors. By contrast, (18)F-FDG PET was false-positive in 4 of 8 patients with benign lesions.
Conclusion: (18)F-FLT uptake correlates better with proliferation of lung tumors than does uptake of (18)F-FDG and might be more useful as a selective biomarker for tumor proliferation.
Comment in
-
PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls.J Nucl Med. 2003 Sep;44(9):1432-4. J Nucl Med. 2003. PMID: 12960188 No abstract available.
Similar articles
-
Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1610-6. doi: 10.1007/s00259-007-0449-7. Epub 2007 May 26. Eur J Nucl Med Mol Imaging. 2007. PMID: 17530250
-
Clinical relevance of imaging proliferative activity in lung nodules.Eur J Nucl Med Mol Imaging. 2005 May;32(5):525-33. doi: 10.1007/s00259-004-1706-7. Epub 2004 Dec 14. Eur J Nucl Med Mol Imaging. 2005. PMID: 15599526 Clinical Trial.
-
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.J Nucl Med. 2005 Jun;46(6):945-52. J Nucl Med. 2005. PMID: 15937304
-
Value of whole-body FDG PET in management of lung cancer.Ann Nucl Med. 2003 Feb;17(1):1-14. doi: 10.1007/BF02988253. Ann Nucl Med. 2003. PMID: 12691125 Review.
-
Current clinical status of 18F-FLT PET or PET/CT in digestive and abdominal organ oncology.Abdom Radiol (NY). 2017 Mar;42(3):951-961. doi: 10.1007/s00261-016-0947-9. Abdom Radiol (NY). 2017. PMID: 27770160 Review.
Cited by
-
Gradient-based delineation of the primary GTV on FLT PET in squamous cell cancer of the thoracic esophagus and impact on radiotherapy planning.Radiat Oncol. 2015 Jan 9;10:11. doi: 10.1186/s13014-014-0304-5. Radiat Oncol. 2015. PMID: 25572431 Free PMC article.
-
Novel Approaches to Imaging Tumor Metabolism.Cancer J. 2015 May-Jun;21(3):165-73. doi: 10.1097/PPO.0000000000000111. Cancer J. 2015. PMID: 26049695 Free PMC article. Review.
-
Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1610-6. doi: 10.1007/s00259-007-0449-7. Epub 2007 May 26. Eur J Nucl Med Mol Imaging. 2007. PMID: 17530250
-
Clinical relevance of imaging proliferative activity in lung nodules.Eur J Nucl Med Mol Imaging. 2005 May;32(5):525-33. doi: 10.1007/s00259-004-1706-7. Epub 2004 Dec 14. Eur J Nucl Med Mol Imaging. 2005. PMID: 15599526 Clinical Trial.
-
[Prognostic values of baseline FDG and FLT PET-CT in diffuse large B cell lymphoma].Zhonghua Xue Ye Xue Za Zhi. 2018 Jan 14;39(1):56-59. doi: 10.3760/cma.j.issn.0253-2727.2018.01.013. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29551036 Free PMC article. Chinese. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical